Navigation Links
Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
Date:5/14/2013

nd its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding the expected use of proceeds from the registered direct offering. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Omeros to Present at the 12th Annual Needham Healthcare Conference
2. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
3. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
4. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
5. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
6. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
7. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
8. Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
9. BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
10. Winding River Productions Announces High-End Studio Enhancements Including SCORM-Compliant e-Learning Media Development and On-Location Data and Media Capture Platforms
11. Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Diagenode, Inc., a leading global ... and complete solutions for epigenetics research, recently launched ... the need for manual processing. The new ChIPettor ... of histones or transcription factors and a semi-automated ...
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:1/22/2015)... 22, 2015   GenoSpace , a precision medicine software company ... the broad use of genomic, imaging and other biomedical data ... Michelle Munson , CEO of Aspera, an IBM Company, ... - http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased ...
(Date:12/25/2014)... 2014 The report “Service Quality Management ... & Provider Type - Global Advancements, Worldwide Forecasts & ... in-depth analysis and forecasting of revenues. , Browse ... pages and in-depth TOC on “Service Quality Management (SQM) ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... NV,(Euronext Brussels: THR), a biotechnology company focused on ... is today issuing a,business update for the nine ... De Haes, CEO of ThromboGenics, commenting on today,s,announcement, ... anticipated. We are now working hard to prepare ...
... 6 AmeriCares has,awarded its annual "Power ... global biotechnology, medical device and specialty pharmaceutical,company. ... Distribution,Management Association,s (HDMA) Annual Leadership Forum in ... award was created by AmeriCares and HDMA ...
... Calif., Nov. 6 ( http://www.amdl.com ),AMDL, Inc. ... with major operations in China and the U.S., ... Douglas MacLellan will present at,Rodman & Renshaw,s Annual ... 2008 at the New York Palace Hotel in ...
Cached Biology Technology:ThromboGenics N.V.: Business Update 2ThromboGenics N.V.: Business Update 3ThromboGenics N.V.: Business Update 4ThromboGenics N.V.: Business Update 5ThromboGenics N.V.: Business Update 6ThromboGenics N.V.: Business Update 7ThromboGenics N.V.: Business Update 8AmeriCares Presents 'Power of Partnership' Award to Baxter 2AmeriCares Presents 'Power of Partnership' Award to Baxter 3AMDL, Inc. New President & CEO Douglas MacLellan to Present at Rodman & Renshaw Annual Global Investment Conference November 12, 2008 2
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
(Date:12/11/2014)... 09, 2014 Research and Markets , ... ) has announced the addition of the "Biometrics ... One major trend emerging in this ... biometric systems utilize more than one characteristic of an ...
(Date:12/10/2014)... a leader in performance biometric data sensor technology, today ... licensees for highly accurate, clinically validated biometric technology. This ... fitness and health sectors, but first responders/military and gaming ... as useful as the biometric data it delivers. As ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Panel of the American Association of Feline Practitioners ... feline patients based on risk assessment., From ... (2013) The American Association of Feline Practitioners, ... released updated guidelines on appropriate feline vaccination schedules ...
... process. Identification of important areas and species with ... objectives. China is one of mega-biodiversity countries of ... environmental degeneration, native and endemic species of China ... decades. It is an urgent agenda to set ...
... JPMorgan Chase & Co. (NYSE: JPM) and the Bill ... allow individual and institutional investors the opportunity to finance ... save millions of lives in low-income countries. ... investors including anchor support from Grand Challenges Canada ...
Cached Biology News:Appropriate vaccinations schedules for feline patients outlined 2Richness mapping and prediction of amphibians in Southern and Central China 2New investment fund will advance late-stage vaccines, other global health technologies 2New investment fund will advance late-stage vaccines, other global health technologies 3New investment fund will advance late-stage vaccines, other global health technologies 4
1M stock solution (238mg/ml)...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Request Info...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Biology Products: